Enestebol
4-hydroxy-17α-methyl-δ1-testosterone, a 17α-alkylated oral AAS closely related to methandienone and oxymesterone that was synthesised but never marketed. Barely studied; the 4-hydroxy group suggests weak aromatisation and mild anti-estrogen character on paper.
01 Overview
Enestebol (4,17β-dihydroxy-17α-methylandrosta-1,4-dien-3-one) is a 17α-methylated derivative of testosterone carrying a 4-hydroxy group and the Δ1 double bond of methandienone. It is essentially a 4-hydroxy methandienone analogue and sits close to oxymesterone chemically.
It was synthesised as an experimental anabolic but never brought to market, so there is virtually no human data. The 4-hydroxy substitution, as in formestane/oxabolone chemistry, tends to reduce or block aromatisation, so estrogenic activity is expected to be low, but this remains inferred rather than demonstrated in people.
02 Mechanism
Oral androgen receptor agonist; 17α-methylation gives oral activity and the 4-hydroxy group is expected to limit aromatisation, biasing the profile toward non-estrogenic anabolic action.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Anecdotal / inferred | 10–30 mg/day | Oral | No clinical dosing; ranges inferred from analogous orals. |
Ester comparison
| Ester | Half-life | Injection freq. | Testosterone by mass |
|---|
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Lean mass / strengthExpected anabolic activity by analogy to methandienone/oxymesterone; no human confirmation. | Unquantified | Preclinical | |
| Low estrogenicity4-hydroxy substitution is expected to limit conversion to estrogen. | Reduced aromatisation | Unconfirmed |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Hepatotoxicity17α-alkylation implies the usual oral-steroid hepatic burden. | Moderate | Common | Preclinical | |
| HPTA suppressionAndrogenic suppression of endogenous testosterone expected. | Moderate | Common | Preclinical |